Since in all of the above studies the terminologies NAFLD/NASH were applied, these definitions will be used in this review
Klin.Wochenschr 12-15-1988;66(24):1202-1211
Given the eminent global opioid crisis, development of GLP-1RA is an important research goal [106]
Nordics Lab Services play a critical role in helping pharmacies achieve the consistency, compliance, and confidence required to safely deliver temperature-sensitive treatments
Lillys Retatrutide: Toward the End of Incremental Metabolic Medicine Why GLP-1++ therapies are redefining what is worth developing and what is not In early December 2025, Eli Lilly announced landmark Phase 3 results for retatrutide its investigational once-weekly triple hormone receptor agonist targeting GLP-1, GIP, and glucagon
There is also a very small increased risk of muscle-related side effects